VivoSeq
Musculoskeletal

Joint Disease

16

Pipeline Programs↗

5

Active Trials↗

12

Companies Involved↗

Joint Disease is an emerging landscape with 16 programs across 12 companies. The most active players are SynAct Pharma Aps, Vitae Pharmaceuticals Inc., an Allergan affiliate, Revance Therapeutics, Inc.. 5 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

15/100

Mech. Concentration

13/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SynAct Pharma Aps

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2R

Revance Therapeutics, Inc.

1 program

Phase 2K

Kang Stem Biotech Co., Ltd.

1 program

Phase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

3 programs

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

16 of 17 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed7 · 54%
Recruiting2 · 15%
Not yet recruiting2 · 15%
Unknown status1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases
Recruiting·IInventera Inc.·Phase 3·NCT07057037·85 enrolled
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Recruiting·—·N/A·NCT06395883·160 enrolled
Short, Medium and Long Term Survivorship of Attune Primary Knee Prosthesis
Active, not recruiting·—·Preclinical·NCT01754363·1,542 enrolled
Pain in Inflammatory Joint Diseases
Not yet recruiting·—·N/A·NCT06718569·350 enrolled
Efficacy of Intra-articular Treatment With Adelmidrol 2% / Hyaluronic Acid 1%, With or Without m/umPEA, in Knee Pain Due to Joint Degeneration: a Bicentric, Prospective, Randomized Study.
Not yet recruiting·UUniversita di Verona·Preclinical·NCT07680101·80 enrolled
Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
Completed·KKolon TissueGene, Inc.·Phase 1·NCT00599248·12 enrolled
Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease
Completed·—·Phase 4·NCT01893996·63 enrolled
Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease
Completed·—·N/A·NCT01389388·114 enrolled
Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease
Completed·UUniversity of Alberta·N/A·NCT00471393·28 enrolled
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00784277·597 enrolled
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Completed·KKolon TissueGene, Inc.·Phase 2·NCT01221441·102 enrolled
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Completed·SSynAct Pharma Aps·Phase 2·NCT04004429·105 enrolled
Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease
Unknown status·TTC Erciyes University·Phase 1/2·NCT05305833·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)